Drug Search Results
More Filters [+]

Adafosbuvir

Alternative Names: adafosbuvir, al-335, al335, al 335
Latest Update: 2022-02-15
Latest Update Note: PubMed Publication

Product Description

Adafosbuvir (AL 335), a monophosphate prodrug, is being developed by Alios BioPharma (a subsidiary of Johnson & Johnson) for the treatment of hepatitis C virus (HCV) infections. Adafosbuvir acts a uridine-based nucleotide analogue polymerase inhibitor. (Sourced from: https://newdrugapprovals.org/tag/alios-biopharma/)

Mechanisms of Action: HCV-NS5B Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Adafosbuvir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis A|Hepatitis C, Chronic

Phase 1: Healthy Volunteers|Other|Kidney Diseases|Hepatitis C, Chronic|Hepatitis A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JapicCTI-163468

P2

Completed

Hepatitis C, Chronic

2018-06-30

AL-335-604

P2

Completed

Hepatitis C, Chronic

2018-05-11

AL-335-604

P2

Completed

Hepatitis C, Chronic

2018-05-11

2016-002845-46

P2

Completed

Hepatitis C, Chronic

2018-05-11

CR108264

P2

Completed

Hepatitis A|Hepatitis C, Chronic

2018-05-07

22%

CR108264

P2

Completed

Hepatitis A|Hepatitis C, Chronic

2018-05-07

22%

Recent News Events